ClinicalTrials.gg
RecruitingNCT07619521Updated Oct 22, 2026

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

A Phase 1/2 interventional study of Biospecimen Collection and Diagnostic Imaging Testing in Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma and Stage III Pancreatic Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Updated Oct 22, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Pancreatic Neoplasms by National Cancer Institute (NCI) — 14 open to participants now, 29 under way, none of them phase 3. Pancreatic Neoplasms · National Cancer Institute (NCI).

Planned enrollment
57th of 101
31 · median 40
Started
2027
the only one that year
Phase 1/2
15 of 114
3 open now
Primary completion
2028-09
later than 19 of 28 live
Registered
114th of 114
by date

Among the 114 studies in Pancreatic Neoplasms by National Cancer Institute (NCI), this one is the 57th largest by planned enrollment of the 101 interventional ones that give a count, is the only one that started in 2027, is one of 15 in phase 1/2, reaches primary completion later than 19 of the 28 other live ones, and was the 114th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

14 of the 114 studies in Pancreatic Neoplasms by National Cancer Institute (NCI) are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Pancreatic Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. DS-8201a is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Giving selumetinib with DS-8201a may be safe, tolerable and/or effective in treating patients with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess dose limiting toxicities (DLTs) and determine the recommended phase 2 dose (RP2D) of the combination of selumetinib (AZD6244 hydrogen sulfate) and DS-8201a (trastuzumab deruxtecan) in patients with pancreatic ductal adenocarcinoma (PDAC). (Escalation phase) II. To assess the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. (Phase II [expansion phase])

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To evaluate the safety and tolerability of the combination of selumetinib (AZD6244 hydrogen sulfate) and DS-8201a (trastuzumab deruxtecan).

III. To determine preliminary signals of efficacy, as measured biochemical (CA 19-9) response, time to response, duration of response, disease control rate, clinical benefit rate, progression free survival (PFS), and overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To evaluate the pharmacodynamic (PD) effect of selumetinib (AZD6244 hydrogen sulfate) plus DS-8201a (trastuzumab deruxtecan).

II. To evaluate the pharmacokinetics (PK) of selumetinib (AZD6244 hydrogen sulfate) plus DS-8201a.

III. To explore biomarkers and genomic alterations associated with treatment response.

OUTLINE: This is a phase I, dose-escalation study of selumetinib with DS-8201a followed by a phase II study.

Patients receive selumetinib orally (PO) twice daily (BID) on days 1-21 of each cycle and DS-8201a intravenously (IV), over 30-90 minutes, on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or multigated acquisition (MUGA) scan, diagnostic imaging and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 12 months.

03

Conditions studied

  • Advanced Pancreatic Ductal Adenocarcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Pancreatic Ductal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Review of eligibility criteria by the study principal investigator (PI) is required prior to enrollment
  • Patients must have or cytologically confirmed adenocarcinoma of the pancreas
  • Patients must have unresectable or disease with KRAS mutation per Next Generation Sequencing (NGS) tumor testing and immunohistochemistry (IHC) positivity (2+ or above for dose escalation and per decision rule for phase II), as determined by a Clinical Laboratory Improvement Act (CLIA)-certified kit using gastric cancer criteria
  • Patients must have that can fulfill (RECIST) version 1.1 criteria
  • Patients must have exposure to at least one for metastatic or unresectable PDAC (for both escalation and phase II cohorts) or a documented patient decision to forego therapy that has an otherwise proven survival advantage (for escalation cohort only)
  • Patients who have received prior topoisomerase inhibitors including irinotecan and nanoliposomal irinotecan will be eligible for this study
  • Only 1 prior line of therapy for metastatic or unresectable PDAC will be allowed for patients in the phase II cohort. or neoadjuvant therapy does not count, assuming it was completed > 6 months prior to the start of systemic therapy for metastatic or unresectable disease
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of selumetinib (AZD6244 hydrogen sulfate) in combination with DS-8201a (trastuzumab deruxtecan) in patients \< 18 years of age, children are excluded from this study
  • (ECOG) performance status ≤ 2 ( ≥ 70%). Regardless of performance status, enrollment should be based on the judgment of the treating physician that the patient will be able to be safely treated with the proposed therapeutic intervention
  • ≥ 9 g/dL (within 14 days of enrollment)

    • No transfusions with red blood cells or are allowed within 1 week prior to screening assessment
  • Leukocytes ≥ 3,000/mcL (within 14 days of enrollment)
  • ≥ 1,500/mcL (within 14 days of enrollment)

    • No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment
  • Platelets ≥ 100,000/mcL (within 14 days of enrollment)
  • Total ≤ 1.5 × institutional (ULN), (\< 3 × ULN in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 14 days of enrollment)
  • (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) \< 5 × ULN in participants with liver metastases (within 14 days of enrollment)
  • Serum albumin ≥ 2.5 g/dL (within 14 days of enrollment)
  • (INR)/Prothrombin Time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (within 14 days of enrollment)
  • Creatine phosphokinase (CPK) ≤ 2.5 × ULN (within 14 days of enrollment)
  • (GFR) ≥ 60 mL/min/1.73 m\^2 (within 14 days of enrollment)
  • -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with treated are eligible if follow-up brain imaging, performed at least 6 months after central nervous system (CNS)-directed therapy, shows no evidence of progression
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must undergo a clinical risk assessment of cardiac function using the (NYHA) Functional Classification. To be eligible, patients must be NYHA Class II or better and have no history of myocardial infarction within 6 months prior to enrollment, no symptomatic congestive heart failure (NYHA Class IIb-IV), and no troponin levels consistent with myocardial infarction (as defined by the manufacturer) within 28 days prior to enrollment
  • Patients must have a baseline (LVEF) ≥ 50% as measured by echocardiogram (ECHO) or mutilated acquisition scan (MUGA) scan within 28 days before randomization/enrollment
  • Patients must be willing to undergo baseline ophthalmic evaluation, including visual acuity and slit-lamp examination
  • The effects of selumetinib (AZD6244 hydrogen sulfate) and DS-8201a (trastuzumab deruxtecan) on the developing human fetus are unknown. For this reason and because MEK inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of (WOCBP) and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 months (for WOCBP) or 4 months (for men) after completion of drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Women of non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone [FSH] > 40 mIU/mL and estradiol \< 40 pg/mL [\< 147 pmol/L] is confirmatory) are eligible. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method
  • Male subjects must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrolment in this study
  • Female subjects must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration
  • Ability to understand and the willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion criteria

Exclusion Criteria:

  • Patients with prior MEK inhibitor, ERK inhibitor, or -directed therapy treatment
  • Patients who have had chemotherapy (including antibody drug therapy, retinoid therapy, hormonal therapy for cancer) within 3 weeks (2 weeks or five half-lives, whichever is longer for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents), weekly paclitaxel; 6 weeks for nitrosoureas or mitomycin C
  • Patients who have had immunotherapy including monoclonal antibody therapy within 4 weeks
  • Patients who have a history of severe reactions to other monoclonal antibodies
  • Patients who have had a major surgery within 4 weeks
  • Patients with a history of allogeneic organ or stem cell transplant
  • Patients who are receiving any other agents or received any other investigational agents within the past 21 days prior to protocol treatment initiation
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib (ADZ6244 hydrogen sulfate) or DS-8201a (trastuzumab deruxtecan)
  • Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment
  • Patients with prior use of medication within 14 days prior to first study dose, except for intranasal and inhaled or systemic corticosteroids at doses less than 10 mg/day of prednisone or equivalent
  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
  • Patients with a interval (QTc) prolongation to > 470 ms (females) or > 450 ms (males) based on average of the screening triplicate 12-lead (ECG)
  • Patients with a history of (non-infectious) interstitial lung disease (ILD) that required steroids, presence of ILD that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity, or where suspected ILD cannot be ruled out by imaging at screening. These patients will be excluded because DS-8201a (trastuzumab deruxtecan) is known to increase the risk of developing ILD and pneumonitis
  • Patients with lung-specific, intercurrent, illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months prior to study enrollment, severe asthma, severe chronic obstructive pulmonary disorder (), restrictive lung disease, significant pleural effusion, etc.), and any , connective tissue, or inflammatory disorders with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), and/or prior pneumonectomy. These patients will be excluded because DS-8201a is known to increase the risk of developing ILD and pneumonitis
  • Patients with gastrointestinal conditions which could impair absorption of selumetinib (AZD6244 hydrogen sulfate) or inability to ingest selumetinib (AZD6244 hydrogen sulfate)
  • Patients with a history of significant retinal pathology (including but not limited to, retinal vein occlusion, retinal detachment, or macular degeneration) or clinically significant ophthalmic abnormalities that may increase the risk of retinal adverse events
  • Active ocular disease requiring systemic therapy or current use of contact lenses that may interfere with ophthalmic evaluations
  • Based on pre-clinical and clinical data, DS-8201a (trastuzumab deruxtecan) and selumetinib (AZD6244 hydrogen sulfate) are associated with ocular toxicity. Patients with clinically significant corneal disease, in the opinion of the investigator, will be excluded from this study
  • Patients who have had chest radiation therapy within 4 weeks (2 weeks for palliative stereotactic body radiation therapy). These patients will be excluded because DS-8201a (trastuzumab deruxtecan) is known to increase the risk of developing pneumonitis
  • Patients with spinal cord compression, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
  • Patients with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Patients that have received a within 30 days prior to the first dose of study drug will be excluded. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed
  • Patients with unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia or peripheral neuropathy) not yet resolved to grade ≤ 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee (e.g., grade 2 chemotherapy-induced neuropathy). Subjects should no longer be symptomatic nor require treatment with corticosteroids or anticonvulsants and must have recovered from the acute toxic effect of radiotherapy
  • Patients with ongoing muscle disorders or elevated baseline creatine phosphokinase (CPK) levels suggestive of rhabdomyolysis or myopathy
  • Patients currently using high-dose vitamin E supplements exceeding the recommended daily intake (≥ 400 IU/day) or concurrent use of anticoagulants/antiplatelets that may increase bleeding risk, unless clinically indicated and closely monitored
  • Pregnant women are excluded from this study because selumetinib (AZD6244 hydrogen sulfate) is a MEK inhibitor agent with the potential for teratogenic or abortifacient effects. Women of must have a negative pregnancy test within 7 days of study entry. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selumetinib (AZD6244 hydrogen sulfate) breastfeeding should be discontinued if the mother is treated with selumetinib (AZD6244 hydrogen sulfate). These potential risks also apply to treatment with DS-8201a (trastuzumab deruxtecan)
  • Patients who have received prior systemic anticancer therapy, investigational agents, or radiotherapy without completion of an adequate prior to study treatment initiation defined as at least 14 days or > 5 half-lives of the prior agent (whichever is shorter). This applies to therapies with potential overlapping toxicities with DS-8201a (trastuzumab deruxtecan) or selumetinib (AZD6244 hydrogen sulfate) including but not limited to agents associated with pulmonary toxicity, cytopenias, or gastrointestinal toxicity
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Treatment (Selumetinib and DS-8201a)

    Patients receive selumetinib PO BID on days 1-21 of each cycle and DS-8201a IV, over 30-90 minutes, on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography or MUGA scan, diagnostic imaging and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Diagnostic Imaging Testing · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Selumetinib · Biological: Trastuzumab Deruxtecan

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureDiagnostic Imaging Testing

    Undergo diagnostic imaging

    Also known as: Diagnostic Imaging, Medical Imaging

  • ProcedureEchocardiography Test

    Undergo echocardiography

    Also known as: EC, Echocardiography

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA scan

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • DrugAZD 6244Studies of AZD 6244AZD 6244 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: ARRY-142886, AZD 6244, AZD-6244, AZD6244, MEK Inhibitor AZD6244

  • Given IV

    Also known as: DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516

06

What researchers measure

Primary outcomes

  1. Occurrence of dose limiting toxicities (DLTs) (dose escalation phase)

    Will provide the number and proportion of DLTs provide and 95% confidence intervals.

    Time frame: From baseline up to day 21

  2. HER2 expression status (dose escalation phase)

    Will be evaluated descriptively during the dose escalation phase with respect to safety, tolerability and preliminary antitumor activity.

    Time frame: Up to 1 year

  3. Overall response rate (phase II)

    Defined as confirmed responses by Response Evaluation Criteria in Solid Tumors version (v) 1.1. A confirmed response requires documentation of a complete response (CR) or partial response (PR) on a subsequent imaging assessment performed at least ≥ 4 weeks after the initial response is observed.

    Time frame: Up to 1 year

Secondary outcomes

  1. Incidence of adverse events

    Safety will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events v 5.0. Descriptive statistics will summarize the frequency and severity of adverse events and serious adverse events, as well as any dose-limiting toxicities. A Clopper-Pearson exact 95% confidence interval for the proportion of subjects exhibiting DLTs will be calculated.

    Time frame: Up to 1 year

  2. Biochemical response

    Will be evaluated by measuring changes in cancer antigen (CA) 19-9 levels. A predefined percentage decrease from baseline (e.g., ≥ 50%) will define response, and response rates will be reported descriptively along with Clopper-Pearson 95% CIs. Patterns of CA 19-9 change over time may be explored as an exploratory analysis.

    Time frame: Up to 1 year

  3. Time to response

    Time frame: From the first dose of study treatment to the first documentation of a confirmed objective response, up to 1 year

  4. Duration of response

    Time frame: From the first documentation of confirmed objective response (CR or PR) to the date of first documented disease progression or death, up to 1 year

  5. Disease control rate

    Defined as the proportion of patients who achieve a best overall response of CR, PR, or stable disease (SD).

    Time frame: Up to 1 year

  6. Clinical benefit rate

    Will be defined as the proportion of patients with a best overall response of CR, PR, or SD lasting at least 24 weeks from the start of treatment.

    Time frame: Up to 1 year

  7. Progression free survival

    The median time to tumor progression and its 95% confidence interval will be calculated using a Kaplan-Meier approach.

    Time frame: From treatment initiation to disease progression or death from any cause, whichever occurs first, up to 1 year

  8. Overall survival (OS)

    Will be estimated using the Kaplan-Meier method, and median OS will be reported along with 95% confidence intervals. A Clopper-Pearson exact 95% confidence interval will be calculated for the 1-year OS rate.

    Time frame: From treatment initiation to death from any cause, up to 1 year

Other outcomes

  1. Selumetinib (AZD6244 hydrogen sulfate) pharmacokinetics (PK)

    Will be analyzed with both non-compartmental and nonlinear mixed effects (NLME) approaches, while DS-8201a PK will be analyzed using NLME to determine individual PK parameters.

    Time frame: Cycle 1 day 1 pre-dose, at 0.5, 1, 2, 3, 4, and 8 hours post dose and at cycle 1 day 1 pre-dose (cycle length = 21 days)

  2. Immunogenicity

    Presence and quantity of anti-drug antibodies (ADA) will be determined.

    Time frame: At cycle 1 day 1 pre-dose, pre-dose at day 1 of cycles 2, 4 and 8 and at progression (phase II only) (cycle length = 21 days)

  3. PK parameters

    Determined for both agents, including estimated DS-8201a payload exposures, along with ADA presence and quantity, will be correlated with safety and efficacy outcomes.

    Time frame: Up to 1 year

  4. Trastuzumab deruxtecan (DS-8201a) clearance

    Including a time-varying rate of change, will be estimated for each patient using nonlinear mixed effects. The methods for this will include adopting published PK models and using Bayesian estimation. Will use the likelihood ratio test for decision-making when adding each new parameter, using the objective function value (OFV), which is chi-square distributed, and a cut-off of -3.84 change in OFV, which corresponds to a p-value of 0.05 with one degree of freedom. Once a base model is established, we will also evaluate covariates (e.g., albumin, creatinine clearance, ADA, etc.) using forward addition/backward deletion with p = 0.01 as a cut-off for covariate retention.

    Time frame: Up to 1 year

  5. Baseline DS-8201a clearance

    Assessed as a continuous variable in univariate and multi-variate Cox proportional hazards models for PFS.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Site Public Contact · Contact412-647-8073
    • Janie Y. Zhang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Sep 2028, 15 months later.

Of 95 non-industry phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 95. This study's planned 15 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2026
First posted
Jun 2, 2026
StartEst.
Jun 1, 2027
Primary completionEst.
Sep 8, 2028
CompletionEst.
Sep 8, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • UPMC Hillman Cancer Center · Pittsburgh, United States
Show 1 removed
  • Yale University Cancer Center LAO · New Haven, United States
across 2 updates, Oct 19, 2026 – Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    1 site removed
    Show 1 removed
    • Yale University Cancer Center LAO · New Haven, United States
  2. Oct 19, 2026
    1 site added
    Show site
    • UPMC Hillman Cancer Center · Pittsburgh, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619521
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 1, 2027 (estimated)
Primary completion
Sep 8, 2028 (estimated)
Completion
Sep 8, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Anup K Kasi Loknath Kumar
principal investigator · Yale University Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD 6244 · Trastuzumab deruxtecan

Start the discussion